NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Soley Therapeutics

Soley Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://soleytherapeutics.com/

Last Round

Series C

Jan 7, 2026

Total Funding Raised

$290M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Soley Therapeutics is a biotechnology company that uses its proprietary cell stress-sensing platform, integrated with AI and automation, to discover and develop first-in-class medicines for oncology, neurodegenerative, and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

drug discoverybiotechnologyoncologysmall molecule therapeuticsbiotechundruggable targetsAI drug discoverypharma R&Dcomputer visionlive-cell imagingdrug pipelinecomputational biologyfirst-in-classtherapeutic developmentbiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Soley Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Soley Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Soley Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 7, 2026
Series ADec 22, 2020

Key People

Founding team and executive leadership

Kurosh Ameri

Founder Co-founder, Chief Scientific Officer, Soley Therapeutics, Inc.

Founding Team

Soley Therapeutics Investors

Notable investors and investment history

Soley Therapeutics investors
InvestorRounds
Surveyor CapitalSeries C
Breyer CapitalSeries B, Series C, Series A
GordonMD Global InvestmentsSeries B, Series C, Series A
HRTG PartnersSeries C
RWN ManagementSeries C
CitadelSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Preclinical data for STX-6398 presented at AACR Annual Meeting 2026.

  • Mar 18, 2026

    STX-6398 targets undruggable CKAP2 for selective anti-tumor activity.

Soley Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Soley Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Soley Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range39
Year Founded2020
Last FundingJan 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.